KCA
CMPX icon

KVP Capital Advisors’s Compass Therapeutics CMPX Stock Holding History

KVP Capital Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Buy
771,000
+271,000
+54% +$800K 1.24% 30
2026
Q1 		$2.65M Buy
+500,000
New +$2.89M 1.98% 19

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

KVP Capital Advisors's CMPX Position: Q2 2026 in Review

KVP Capital Advisors increased its Compass Therapeutics (CMPX) stake by 54% in Q2 2026, buying an estimated $800K and bringing the position to 771,000 shares worth $1.69M. The position accounts for 1.24% of the portfolio, ranked #30.

KVP Capital Advisors first reported a position in CMPX in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.65M in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • KVP Capital Advisors held 771,000 shares of Compass Therapeutics worth $1.69M as of Q2 2026.
  • KVP Capital Advisors bought 271,000 Compass Therapeutics shares in Q2 2026, an estimated $800K.
  • Compass Therapeutics made up 1.24% of KVP Capital Advisors's portfolio in Q2 2026, its #30 holding.
  • KVP Capital Advisors first reported a position in Compass Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • KVP Capital Advisors's Compass Therapeutics position peaked at $2.65M in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on KVP Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.